Retatrutide — nicknamed "Triple G" — has posted the largest weight-loss results ever seen from a medication, with about 28% average weight loss in its main phase 3 trial. Dr. Judith Borger breaks down how this investigational triple agonist works on GIP, GLP-1, and glucagon, what the phase 2 and phase 3 studies show, how it compares to semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro), and why the "research peptide" versions sold online are a real risk.

In this episode

• How semaglutide and tirzepatide work, and the step from single to dual to triple agonist
• Why glucagon is the surprising — and important — third hormone
• Results from TRIUMPH-1 through -4 and TRANSCEND-T2D-1
• Side effects, including dysesthesia and what it means for your skin
• What's still unknown: head-to-head data, heart outcomes, lean mass
• The legal landscape

Dr. Judith Borger Links:

www.theaestheticdoctor.com

www.instagram.com/doctorborger

Fall has a way of sneaking up — school schedules ramp up, extracurriculars are in full swing, and the to-do list gets longer, leaving many feeling stressed and depleted. In this episode of the Aesthetic Doctor Podcast, Dr. Borger keeps it free-flowing and honest, talking through why this season feels so overwhelming for busy moms and sharing wellness tips that actually fit into a packed day.

She covers:

• Why fall hits different — the collision of school schedules and increasing expectations
• Realistic ways to find pockets of wellness without adding another task to your plate (movement, breathing, sleep, and lowering the bar on what "counts")
• Martha Beck's Better - Barter - Bag concept, and how trading small favors and support can lighten the mental load
• A few other favorite tips from Dr. Borger for staying grounded when everything feels like a lot

Dr. Judith Borger Links:

www.theaestheticdoctor.com

www.instagram.com/doctorborger

Dr. Judith Borger breaks down what peptides actually are at the molecular level, unpacks the fast-moving and often confusing FDA regulatory landscape around peptide compounding in 2026, and gives an evidence-based rundown of the most talked-about peptide products and stacks — including “Glow” (GHK-Cu), “Wolverine” (BPC-157/TB-500), CJC-1295/Ipamorelin, PT-141, and the GLP-1s.

In This Episode:

• What peptides are and how they differ from proteins and amino acids
• Why some peptides act as hormones, antioxidants, or signaling molecules in the body
• The current FDA regulatory status of peptide compounding, including the 503A Bulk Drug Substances List and the 2026 Pharmacy Compounding Advisory Committee review
• Why “removed from the safety watch-list” is not the same as “approved for compounding”
• The difference between a peptide from a licensed compounding pharmacy versus an unregulated online vendor
• A breakdown of popular peptide products: Glow (GHK-Cu, glutathione, and vitamin C — sometimes also including BPC-157 and TB-500), Wolverine (BPC-157 + TB-500), CJC-1295/Ipamorelin, PT-141 (bremelanotide/Vyleesi), and GLP-1s (semaglutide, tirzepatide)
• Why “Glow” and “Wolverine” aren't always separate products — some Glow formulations fold in the same BPC-157/TB-500 combination sold as Wolverine
• What real human clinical evidence exists for each — and where the evidence is limited to animal studies or mechanistic theory

• Disclaimer: This episode is for educational purposes only and does not constitute medical advice. Regulatory status discussed reflects information available as of August 2026 and is subject to change; listeners should confirm current FDA guidance and consult a licensed physician before considering any peptide therapy.

Dr. Judith Borger Links:

www.theaestheticdoctor.com

www.instagram.com/doctorborger